Kornimate/medical-research-clean huggingface dataset:
relief of pain in patients with cervical dystonia through the use of transcutaneous electric nerve stimulation (tens)

Conditions: Cervical Dystonia; Pain

Summary: dystonia is a chronic neurological condition that impacts the quality of life due to decreased mobility, social repercussions caused by others's perception of abnormal involuntary movement and frequent pain. botulinum toxin has been shown to be effective in reducing pain in dystonia. however, many patients remain painful despite the injections, especially when the decrease in the effect of the latter, performed every 3 months on average. despite frequent use of tens in pain relief, only a few small studies studying tens in dystonia were published and none of them reported tens effects on dystonic pain using sensory threshold. this study aimed to quantify the efficacy and tolerance of tens in the indication of pain related to dystonia, focusing on cervical dystonia which is the most common form of dystonia.

tendys (tens use in cervical dystonia) is an observational, prospective, single arm, monocentric study including subjects between september 2019 and july 2020 with cervical dystonia treated or not with botulinum neurotoxin (bont) type a at the nancy regional university hospital. all patients who benefited from a simple follow-up or injections of bont every 3 or 4 months for a painful cervical dystonia were proposed the use of tens during a neurologic consultation with one of two specialist physicians trained to cervical dystonia. patients who accepted had to give informed consent and were re-evaluated about 1 month later to ensure that pain persisted and to have a demo of tens. the electro-stimulator was delivered to posterior cervical muscles over or close to the painful site, according to a conventional or high frequency/low intensity mode (gate control). patients were encouraged to use the machine daily, as often and long and possible, except for sleeping and driving. follow-up assessments of pain occurred at the consultation toxin injection 3 months later and at 4 months for all patients.

Eligibility criteria:
inclusion criteria: * patient having received complete information on the organization of the research and not having objected to the exploitation of the data * patient admitted to neurology consultation for cervical dystonia treated with botulinum toxin exclusion criteria: * patient under legal protection * minor patient * patient refusing to give consent * patient with exclusive radicular or truncal involvement * missing data or absence of established reactogenic threshold

Keywords: cervical dystonia pain tens
functional outcomes of knee protheses for malignant tumours of bone

Conditions: Knee Disease; Bone Cancer

Summary: the placement of mega knee prosthesis is a necessity after a large tumor resection and oncological. these mega knee prostheses implanted in the context of oncological surgery have been very few evaluated in the literature. active knee extension is essential in order to walk properly. the study propose the evaluation of this prosthesis by checking the possibility of locking of the prosthetic joint and thus the possibility of active walking. a more in-depth, isokinetic analysis at 1 year of follow-up will also be done in an exploratory manner, as the literature has no data on this subject.


Eligibility criteria:
inclusion criteria: * patient with mutars® modular reconstruction prostheses following primary or secondary knee bone malignancy with minimal follow-up of one year, * cardiological follow-up including at least one ecg and a clinical examination of less than 1 year (ability to perform the isokinetic test), * written informed consent from patient, * socially insured patient, * patient willing to comply with all study procedures and study duration. exclusion criteria: * - underage, * less than a one-year follow-up after surgery (stability of results is not achieved if follow-up is less than one year), * meniscal lesion knee healthy side, * prosthetic surgery of the knee healthy side, * patient with an unbound fracture, * patient without cardiological follow-up, * pregnant or breastfeeding woman, * inability to receive information, consent and participate in the whole study, * no social insurance cover, * no written consent, * person under judicial protection or deprived of liberty.

Keywords: tumour prosthese replacement functional outcomes knee isokinetic
adverse health effects of mainstream and secondhand hookah smoke in nyc hookah bars

Conditions: COPD

Summary: the primary purpose of this study is to examine the health effects of mainstream and secondhand hookah (i.e. water pipe) smoke on pulmonary and cardiovascular functions as well as serum levels of inflammatory biomarkers. investigators would like to demonstrate that inhalation of both mainstream and secondhand smoke generated by hookah produces adverse pulmonary and cardiovascular effects and alterations in serum levels of inflammatory biomarkers.

a total of 20 participants are going to be enrolled in this study; 10 participants smoke hookah and 10 participants are exposed to second hand hookah smoke for 2 hours in nyc hookah bars. subjects in the control group will also be paired as they were for the hookah bar visit but will visit a control location, where they will be asked to consume a similar amount of food and drink at a wine bar. pulmonary function, cardiovascular changes, and blood and urine markers of inflammatory mediators before, immediately after and 24 hours after the participants' visits to hookah bars and wine bars will be examined. air quality monitoring will also be performed at the hookah bar and at the control location. physiological changes will be assessed by measuring pulmonary function, blood pressure, heart rate, and blood oxygenation status. to determine the extent of tobacco exposure and associated inflammatory changes from secondhand hookah smoke, investigators will measure blood inflammatory biomarkers, oxidative stress, gene expression, tobacco-related carcinogenic metabolites, and exhaled carbon dioxide levels.

Eligibility criteria:
inclusion criteria: * competent adult english speaking subjects * have used hookah in the past exclusion criteria: * age \<21 * pregnancy * current cigarette smokers * has pulmonary disease, such as asthma or chronic obstructive pulmonary disease (copd) * subjects are unable to give voluntary informed consent because they are non english speaking, are unable to read or write, or any other impediments that prohibits giving written informed consent * recent nasal surgery (within 6 months) * history of bleeding or other blood related disorder.

Keywords: chronic obstructive pulmonary disease (copd) smoking secondhand smoke
efficacy of letermovir in preventing cytomegalovirus (cmv) infection in lung transplant recipients vs. valganciclovir.

Conditions: Infections, Cytomegalovirus

Summary: the goal of this quasi-experimental multicenter before-after cohort study, phase ii study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (d+/r-) compared to a historical cohort of lung transplant recipients (d+/r-) who received 12 months of valganciclovir prophylaxis to prevent cmv disease."


Eligibility criteria:
inclusion criteria (prospective cohort): * adults over 18 years old * lung transplant recipients (d+/r-) pre-transplant. * having an undetectable cmv polymerase chain reaction assay (pcr) within the 96 hours prior to the start of letermovir prophylaxis. * patients who have provided written informed consent. exclusion criteria (prospective cohort): * hiv-infected patients. * patients with multivisceral transplant. * patients unable to comply with the follow-up protocol. * receiving a different antiviral prophylaxis other than ganciclovir prior to letermovir prophylaxis. * patients with concurrent renal and hepatic insufficiency. inclusion criteria (retrospective cohort): * adults over 18 years old. lung transplant recipients (d+/r-) pre-transplant. * patients treated with valganciclovir prophylaxis for 12 months. * patients transplanted within 2 years prior to the start of the study. * patients with a complete 13-month follow-up and comparable data to the prospective cohort to evaluate the study's primary variables. exclusion criteria (retrospective cohort): * hiv-infected patients. * patients with multivisceral transplant.

Keywords: lung transplant cmv prophylaxis cytomegalovirus
improving quality of life after thoracic surgery using patient-reported outcomes

Conditions: Thoracic Surgery

Summary: this study is designed to test if patient-reported outcomes with automated reporting to clinicians for remote monitoring of postoperative symptoms is feasible and improves quality of life, health outcomes, and service utilization in thoracic surgery patients. patients undergoing thoracic surgery will be asked to self-report symptoms for remote monitoring by their care team.

this is a single center, randomized feasibility study. a total of 140 patients undergoing thoracic surgery will be prospectively enrolled and randomized in a 1:1 ratio to one of two arms. all participants will complete patient-reported outcome (pro) symptom monitoring. the two arms are 1) active symptom monitoring and 2) passive symptom monitoring. the participants randomized to active symptom monitoring will have alerts sent to their clinicians when their pro symptom scores exceed baseline postoperative scores (when discharge day scores are available) by 2 points or more, or when 'severe' or 'very severe' symptoms are reported. participants randomized to the passive pro monitoring arm will complete the same pros as participants in the active monitoring arm, but will not have alerts sent to their clinician. all participants will be administered survey instruments to assess quality of life, satisfaction, and health history. in addition, a subset of up to 40 participants will be chosen at 2 months postoperatively to complete a semi-structured interview about their postoperative symptom reporting experience.

Eligibility criteria:
inclusion criteria: * 18 years or older * english speaking * able and willing to complete web-based symptom survey * be presenting for inpatient thoracic surgery exclusion criteria: * not completing planned surgery within 3 months of obtaining informed consent * diagnosis of esophageal cancer * inability to read and speak english * presenting for a day surgery * presenting for foregut surgery (e.g. paraesophageal hernia repair) * dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent. * current incarceration * pregnancy

Keywords: patient-reported outcomes
ascending ramus versus chin cortical plates for reconstruction of atrophic maxilla

Conditions: Atrophy of Edentulous Maxillary Alveolar Ridge

Summary: assessment of ascending ramus cortical plate for reconstruction of atrophic maxillary ridges versus chin cortical plates (randomized clinical trial)

assessment of ascending ramus cortical plate for reconstruction of atrophic maxillary ridges versus chin cortical plates (randomized clinical trial) to know what is better and more efficient chin or ascending ramus cortical plates.

Eligibility criteria:
inclusion criteria: * patients with atrophic maxilla with residual bone height from 3 to 4mm. * both sexes exclusion criteria: * intraoral soft and hard tissue pathology. * systemic condition that contraindicate implant basement. * psychiatric problems

Keywords: atrophic, augmetation, bone regeneration
drivers of eosinophilic copd exacerbations

Conditions: COPD Exacerbation; Eosinophilia

Summary: main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic copd exacerbations and other subtypes.

main objective: investigate gene expression differences in nasal epithelium and sputum between eosinophilic copd exacerbations and other subtypes to better understand why some patients are more at risk for eosinophilic copd exacerbations. secondary objectives: 1. investigate differences in microbiome composition and immunophenotyping profiles in peripheral blood per subtype. 2. assess for clinical differences between all copd exacerbation subtypes. 3. assess if and how baseline meta-transcriptomics either in nasal epithelium or sputum and blood immunophenotyping can be utilized to predict copd exacerbation subtype. 4. determine if the microbiome in sputum and nasal epithelial material are comparable. 5. determine if different subtypes of copd exacerbations respond differently to standard treatment with oral prednisolone (40 mg daily) with or without antibiotics. 6. to evaluate if metabolic responses during recovery are different in patients with increased systemic inflammation compared to patients without systemic inflammation at exacerbation

Eligibility criteria:
inclusion criteria: 1. copd patient admitted to the hospital for an acute exacerbation of copd 2. physician diagnosed copd according to the gold 2020 guidelines, including symptoms consistent with copd, post-bronchodilator fev1 \< 80% predicted and fev1/fvc \< 70%. 3. age \> 40 years. 4. smoker or ex-smoker, ≥ 10 pack years of smoking. exclusion criteria: 1. current asthma, or prior physician diagnosis of asthma without a symptom- free interval of at least 10 years before the age of 40. 2. chronic use of prednisolone. 3. use of systemic corticosteroids ≥4 days prior to hospital admission. 4. necessity (upon hospitalization) for non-invasive ventilation or icu admission. 5. pneumonia at presentation documented by chest roentgenography. 6. any other clinically relevant lung disease deemed to interfere with the concept of the study design. 7. allergy to systemic corticosteroids or to antibiotics. 8. females of childbearing potential without an efficient contraception unless they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum fsh \>40 miu/ml or the use of one or more of the following acceptable methods of contraception: 1. surgical sterilization (e.g. bilateral tubal ligation, hysterectomy). 2. hormonal contraception (implantable, patch, oral, injectable). 3. barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/cream/suppository. 4. continuous abstinence 9. pregnancy or lactation. 10. known immunodeficiency. 11. life expectancy less than 60 days
psychiatric manifestations associated with behcet's disease

Conditions: Behçet's Disease, neuroBehcet, Anxiety, Depression, Tiredness

Summary: the psychobehçet'study is aimed at evaluating the psychological and neurocognitive symptoms in 25 consecutive patients followed for behçet's disease. this is a monocentric, observational, non interventional study.

patients will be evaluated during a day-care facility for behçet's disease activity together with evaluation of anxiety and depression symptoms (scl90-r and mini assessments), fatigue (mfi) and quality of life (sf36).

Eligibility criteria:
inclusion criteria: * adult male or female * regular follow-up in the internal medicine department of bicetre hospital * diagnosed with behçet's disease exclusion criteria: * refusal to participate in the study * poor command of the french language * patients under legal protection * pregnant woman
drug holidays in the treatment with alendronate in postmenopausal women with osteoporosis

Conditions: Osteoporosis

Summary: the purpose of this study is to determine the duration of the treatment with alendronate in postmenopausal women with osteoporosis.

the duration of the treatment with alendronate is not well established. the investigators recruited 228 women with postmenopausal osteoporosis. they all received alendronate during the first 3 years of monitoring and were later on randomized to whether different regimens of intermittent treatment or to carry on 3 years more.

Eligibility criteria:
inclusion criteria: * postmenopausal osteoporosis under densitometric criteria of the world health organization exclusion criteria: * secondary osteoporosis * alteration in analytic parameters (total proteins, calcium, phosphorus, vitamin d, parathyroid hormone, thyroid hormone, transaminase, creatinine)

Keywords: osteoporosis postmenopausal alendronate
hydrogen-rich water and treatment of mucositis caused by radiation therapy in head and neck cancer patients

Conditions: Mucositis Oral

Summary: this study explores the effects of hydrogen-rich water on alleviating the radiation-induced acute mucositis in head and neck cancer patients


Eligibility criteria:
inclusion criteria: * diagnosis of a biopsy proven head and neck cancer, early or advanced stage, primary or recurrent tumor, * planning to receive daily fractionated radiotherapy for over 4 weeks' duration * karnofsky performance score (kps) of at least 70 * able to describe pain * able to swallow food and water * able to sign consent exclusion criteria: -

Keywords: head and neck cancer radiation therapy supportive care
the role of the cervical spine in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndromes

Summary: this randomized clinical trial will investigate changes in hand function, active cervical range of motion and pinch grip force after the application of physical therapy in women with carpal tunnel syndrome (cts). the purpose of this study is to compare changes in function, cervical range of motion and pinch grip force induced after the application of a physical therapy program including manual therapies targeted to those areas related to the median nerve or after endoscopic surgery in women with cts at medium and long-term follow-up. the hypothesis is that manual therapy is more effective for increasing cervical range of motion and pinch grip force, but similarly effective for improving function, than surgical treatment in women with cts.

there is some evidence suggesting that cts is associated with restricted cervical range of motion and deficits in pinch grip force. in fact, restricted cervical range of motion and deficits in pinch grip force seems to be independent of electro-diagnostic findings. these findings would be associated with the proposed "double crush syndrome" theory. however no longitudinal studies have been conducted. further it has been demonstrated that hand function is associated to deficits in these outcomes. since previous studies support the use of physical therapy and surgical interventions for the management of function in these patients, the aim of this study is to conduct a randomized clinical trial to determine if changes in hand function are related to changes in active cervical range of motion and pinch grip force after the application of a physical therapy program including manual therapies targeted to those areas related to the median nerve or endoscopic surgery in women with cts.

Eligibility criteria:
inclusion criteria: * pain and paresthesia in the median nerve distribution * positive tinel sign, * positive phalen sign, * symptoms had to have persisted for at least 6 months * deficits of sensory and motor median nerve conduction according to guidelines of the american association of electrodiagnosis, american academy of neurology, and the american physical medicine and rehabilitation academy exclusion criteria: * any sensory/motor deficit related to the ulnar or radial nerve; * older than 65 years of age; * previous surgical intervention, steroid injections or physical therapy intervention * multiple diagnoses of the upper extremity (eg, cervical radiculopathy); * history of neck, shoulder, or upper limb trauma (whiplash); * history of any systemic disease causing cts (eg, diabetes mellitus or thyroid disease); * history of other systemic conditions (eg, rheumatoid arthritis, fibromyalgia); * pregnancy
new markers to measure clotting in patients with the obstructive sleep apnoea hypopnoea syndrome

Conditions: Obstructive Sleep Apnoea Hypopnoea Syndrome; Biomarkers of Fibrin Clot Structure; Biomarkers of Vascular Endothelial Injury

Summary: obstructive sleep apnoea hypopnoea syndrome(osahs)affects at least 4% of males and 2% of females. osahs is the combination of excessive daytime sleepiness, snoring and apnoeas (stopping breathing at night). as well as affecting tiredness, mood, concentration and quality of life - there is growing concern that it can increase the risk of high blood pressure, heart problems, strokes and thromboses (clots in the veins). it appears that osahs may affect the thickness of the blood and cause it to clot more easily it also causes damage to the lining of the blood vessels (endothelial injury). these effects seem independent of other risk factors such as obesity, smoking, family history of clots etc. the investigators are testing new biomarkers: gel point and fractal dimension developed at the swansea university to measure the 'clotting' of the blood in people with osahs and a similar group of people who snore and who are sleepy but do not have osahs on sleep studies (controls) also markers of vascular inflammation are being measured.

primary objective: the primary outcome of this study is to test the null hypothesis that no significant difference exists between fractal dimension (df)and vascular injury markers including serum amyloid a (saa), c-reactive protein (crp), vascular cell adhesion molecule-1 (vcam-1) and intercellular adhesion molecule-1 (icam-1)in patients with osahs and sleepy, snoring controls of similar age, gender and bmi. secondary objectives: 1. to test the null hypothesis that there is no significant difference in measured markers before and after a night's sleep in osahs and controls. 2. to test the null hypothesis that there is no significant difference in measured markers following 1 month of cpap treatment, in those with osahs.

Eligibility criteria:
inclusion criteria: * 18-80 year old with h/o daytime sleepiness, snoring and apnoeas exclusion criteria: * refusal to give written informed consent. * personal or family history of pro- thrombotic or bleeding disorders, severe liver disease (clotting problems) and those prescribed warfarin or heparin. * those with borderline sleep studies (4% diprate or ahi 10-14 per hour). * aged less than 18 years or greater than 80 years.

Keywords: clot structure haemostasis gel point fractal dimension serum amyloid a c-reactive protein vascular cell adhesion molecule-1 intercellular adhesion molecule-1